Vivos Therapeutics, Inc. (VVOS) - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held on November 4, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Littleton, Colorado.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the September 8, 2025 record date, 7,504,807 shares were entitled to vote. Approximately 4,968,728 shares were present or represented by proxy, constituting a quorum. Stockholders approved three proposals:
- Election of Directors: Six nominees (R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow, and Dr. Matthew Thompson) were elected to one-year terms. Significant broker non-votes (1,996,649 shares) were recorded for all director nominees.
- Equity Plan Amendment: Stockholders approved an amendment to the 2024 Omnibus Equity Incentive Plan with 2,453,436 shares voting for and 516,368 against.
- Auditor Ratification: The appointment of Baker Tilly US, LLP (successor to Moss Adams LLP) as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 4,861,139 shares voting for and 102,827 against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the annual meeting results.
Investor Verification Checklist
- Verify the specific terms of the amendment to the 2024 Omnibus Equity Incentive Plan approved by stockholders.
- Confirm the transition details between Moss Adams LLP and Baker Tilly US, LLP regarding the audit of the fiscal year ending December 31, 2025.
- Review the Company's upcoming 10-K filing for the fiscal year ended December 31, 2025, to obtain financial performance data not included in this 8-K.
- Note the high volume of broker non-votes (approx. 1.99 million shares) on director elections, which may indicate institutional investors did not exercise voting discretion on these matters.